The Russian Direct Investment Fund, RDIF and Indian Biotechnology company Panacea Biotec have announced the launch of production of the Russian COVID vaccine Sputnik V in India.
This move will boost the production of vaccines and help in facilitating the supply of Sputnik-V. In collaboration with the RDIF, Panacea Biotec will produce 100 million doses of Sputnik V per year.
In a statement issued by Russia’s sovereign wealth fund RDIF, the first produced batch of vaccine by the Panacea Biotec’s facilities at Baddi will be shipped to the Gamaleya Center for quality control.
Managing Director of Panacea Biotec Dr. Rajesh Jain has said, this marks a significant step as company has initiated production of Sputnik V.
He said, together with RDIF, they hope to help bring a sense of normalcy back to people across the country and around the world.
CEO of the Russian Direct Investment Fund Kirill Dmitriev, said launch of production in India in partnership with Panacea Biotec marks an important step in helping the country fight against the pandemic.
Sputnik V has been granted the emergency use authorization by the Drugs Controller General of India. The first dose of Sputnik V was administered in India on 14th May of this month.